Related Experiment Video
Updated: Apr 7, 2026
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Myelodysplastic Syndromes: Diagnosis and Treatment
1Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.
Abstract:
In the past few years, new biological insights into the myelodysplastic syndromes (MDS) resulting from molecular genetic analysis have improved pathologic understanding, but treatment advances have not kept pace. More than 40 genes are now known to be recurrently mutated in MDS. However, because most of these genes encode spliceosome components, chromatic remodeling factors, epigenetic pattern modulators, or transcription factors rather than more easily inhibited activated tyrosine kinases, there are as of yet few narrowly targeted therapies available for MDS. Three drugs--azacitidine, decitabine, and lenalidomide--were approved by the US Food and Drug Administration for MDS indications a decade ago, and these agents can improve hematopoiesis, delay disease progression, and improve survival and quality of life for a subset of patients. However, only a few patients with MDS respond to these agents, and their benefit is temporary. The only potentially curative therapy for MDS is allogeneic hematopoietic stem cell transplant, but owing to the advanced age of many patients with MDS and the frequency of serious comorbid conditions, less than 10% of patients currently undergo stem cell transplant. This narrative review summarizes the current understanding of MDS and treatment options for these challenging disorders.
Insights
Molecular insights into myelodysplastic syndromes (MDS) have advanced, yet effective treatments remain limited. Current therapies offer temporary benefits for a few, highlighting the need for novel therapeutic strategies for MDS patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Recent molecular genetic analyses have significantly improved the understanding of MDS pathogenesis.
- Despite advances in understanding, therapeutic options for MDS remain limited.
Purpose of the Study:
- To review the current understanding of myelodysplastic syndromes (MDS).
- To summarize the existing treatment options for MDS.
- To highlight the challenges in developing targeted therapies for MDS.
Main Methods:
- This is a narrative review.
- Information was gathered from recent literature on MDS.
- Focus is on molecular insights and current treatment landscape.
Main Results:
- Over 40 genes are recurrently mutated in MDS, often encoding spliceosome components or epigenetic regulators.
- Approved therapies like azacitidine, decitabine, and lenalidomide benefit only a subset of patients temporarily.
- Allogeneic hematopoietic stem cell transplant is the only curative option but is suitable for less than 10% of patients.
Conclusions:
- Current treatments for MDS provide limited efficacy and temporary benefits.
- The genetic complexity of MDS, involving spliceosome and epigenetic factors, hinders the development of targeted therapies.
- There is a critical need for novel and more effective therapeutic strategies for myelodysplastic syndromes.
